Critical Survey: Apyx Medical (NASDAQ:APYX) and Accuray (NASDAQ:ARAY)

Apyx Medical (NASDAQ:APYX) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Earnings & Valuation

This table compares Apyx Medical and Accuray’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apyx Medical $16.69 million 13.72 $64.01 million ($0.29) -23.28
Accuray $418.79 million 0.56 -$16.43 million ($0.15) -17.73

Apyx Medical has higher earnings, but lower revenue than Accuray. Apyx Medical is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Apyx Medical has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.

Insider & Institutional Ownership

51.1% of Apyx Medical shares are owned by institutional investors. Comparatively, 79.0% of Accuray shares are owned by institutional investors. 6.0% of Apyx Medical shares are owned by company insiders. Comparatively, 3.3% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Apyx Medical and Accuray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apyx Medical 255.57% -14.88% -13.14%
Accuray -3.92% -26.69% -3.18%

Analyst Recommendations

This is a summary of recent ratings and price targets for Apyx Medical and Accuray, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apyx Medical 0 0 3 0 3.00
Accuray 0 3 0 0 2.00

Apyx Medical currently has a consensus price target of $8.00, indicating a potential upside of 18.52%. Accuray has a consensus price target of $3.95, indicating a potential upside of 48.50%. Given Accuray’s higher possible upside, analysts clearly believe Accuray is more favorable than Apyx Medical.

About Apyx Medical

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with's FREE daily email newsletter.